Acellera Therapeutics specializes in accelerating drug discovery through advanced computational methods, particularly leveraging AI and quantum chemistry. Their flagship platform, QuantumBind®, is designed for small-molecule discovery and potency optimization, combining the precision of quantum chemistry with the rapid processing capabilities of artificial intelligence and machine learning. This innovative approach allows Acellera to significantly reduce the time required to identify lead molecules, enabling clients to progress from target identification to a prioritized list of lead candidates within weeks. The company has demonstrated its capabilities by collaborating with numerous top pharmaceutical and biotech firms, addressing complex challenges in drug discovery.

In addition to their QuantumBind® platform, Acellera employs a range of sophisticated technologies to enhance drug discovery processes. These include mixed-solvent molecular dynamics simulations for exploring protein conformational spaces, gigascale virtual screening to identify potential hits across vast chemical libraries, and multi-parametric optimization for lead candidates. Their expertise extends to generative AI for drug design, machine learning scoring models, and predictive models for ADME (absorption, distribution, metabolism, and excretion) properties. Acellera's commitment to open science is evident through their contributions to open-source projects and collaborations with academic institutions, further solidifying their role as a leader in computational drug discovery.

Spain

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

Acellera Therapeutics

Company Details